Liraglutide Therapy and Weight Control in Adolescents with Severe Obesity: A Real-World Experience

OBJECTIVE: Adolescent obesity remains a major clinical challenge, with limited effective treatment options beyond lifestyle modification. Liraglutide, a glucagon-like peptide-1 receptor agonist approved for adolescents aged ≥ 12 years, has shown promising results in clinical trials; however, real-world data remain scarce. This study aimed to evaluate the real-world effectiveness and tolerability of liraglutide in adolescents with severe obesity, including weight, body composition, and metabolic outcomes. METHODS: This retrospective longitudinal cohort study included adolescents with obesity aged 12-19 years who received liraglutide therapy. Anthropometric, biochemical, body composition, and adverse event data were assessed monthly. RESULTS: A total of 29 adolescents with obesity (13 males) were included (mean age: 15.7 ± 2.0 years; mean body mass index (BMI): 38.6 ± 6.0 kg/m2; body mass index standard deviation score (BMI-SDS): 3.38 ± 0.57). - BMI-SDS decreased progressively, with an estimated reduction of 0.46 from baseline to month 6; the decline was numerically faster in the first 3 months than in months 3-6, without reaching statistical significance (P = .11). Lean mass percentage increased and total fat percentage decreased after 3 months (both P < .05). Total cholesterol, fasting insulin, and homeostasis model assessment of insulin resistance decreased significantly, while other metabolic parameters remained unchanged. Gastrointestinal adverse events were common; 3 patients discontinued due to intolerance and 1 due to gallstones. CONCLUSION: In this real-world cohort, liraglutide treatment was associated with early and clinically meaningful reductions in BMI-SDS and improvements in insulin sensitivity in adolescents with severe obesity. The therapy was generally well tolerated, though gastrointestinal side effects and financial barriers limited treatment persistence. Longer-term prospective studies are needed to assess durability and cardiometabolic outcomes.

Authors

Institutions

Publication Details

Journal
Turkish Archives of Pediatrics
Published
2026-11-19
DOI
https://doi.org/10.65717/turkarchpediatr.2026.26191
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Liraglutide Therapy and Weight Control in Adolescents with Severe Obesity: A Real-World Experience

Ilayda Altun, Gökçe Velioğlu Haşlak, Hande Turan, Hasan Karakaş et al.
5 links
Turkish Archives of Pediatrics
Pharmacology and Obesity Treatment
article

Liraglutide Therapy and Weight Control in Adolescents with Severe Obesity: A Real-World Experience

Ilayda Altun, Gökçe Velioğlu Haşlak, Hande Turan, Hasan Karakaş, Olcay Evliyaoğlu, Elvan Bayramoğlu, Gürkan Tarçın, Didem Güneş Kaya, Mert Uçar
article en

Abstract

OBJECTIVE: Adolescent obesity remains a major clinical challenge, with limited effective treatment options beyond lifestyle modification. Liraglutide, a glucagon-like peptide-1 receptor agonist approved for adolescents aged ≥ 12 years, has shown promising results in clinical trials; however, real-world data remain scarce. This study aimed to evaluate the real-world effectiveness and tolerability of liraglutide in adolescents with severe obesity, including weight, body composition, and metabolic outcomes. METHODS: This retrospective longitudinal cohort study included adolescents with obesity aged 12-19 years who received liraglutide therapy. Anthropometric, biochemical, body composition, and adverse event data were assessed monthly. RESULTS: A total of 29 adolescents with obesity (13 males) were included (mean age: 15.7 ± 2.0 years; mean body mass index (BMI): 38.6 ± 6.0 kg/m2; body mass index standard deviation score (BMI-SDS): 3.38 ± 0.57). - BMI-SDS decreased progressively, with an estimated reduction of 0.46 from baseline to month 6; the decline was numerically faster in the first 3 months than in months 3-6, without reaching statistical significance (P = .11). Lean mass percentage increased and total fat percentage decreased after 3 months (both P < .05). Total cholesterol, fasting insulin, and homeostasis model assessment of insulin resistance decreased significantly, while other metabolic parameters remained unchanged. Gastrointestinal adverse events were common; 3 patients discontinued due to intolerance and 1 due to gallstones. CONCLUSION: In this real-world cohort, liraglutide treatment was associated with early and clinically meaningful reductions in BMI-SDS and improvements in insulin sensitivity in adolescents with severe obesity. The therapy was generally well tolerated, though gastrointestinal side effects and financial barriers limited treatment persistence. Longer-term prospective studies are needed to assess durability and cardiometabolic outcomes.

Turkish Archives of Pediatrics
Istanbul University-Cerrahpaşa (TR), Kocaeli Üniversitesi (TR), Istanbul University (TR)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon